Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line

Anticancer Research

Volumn 21, Issue 4 A, 2001, Pages 2463-2469

  Tanaka, T ^a   Masuda, H ^a   Naito, M ^a   Tamai, H ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

5 FU; Cisplatin; Cisplatin resistance; DNA repair; Human ovarian cancer cells; Reversal of CDDP resistance

Indexed keywords

CISPLATIN; FLUOROURACIL; GLUTATHIONE; PLATINUM;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; DNA BINDING; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLUOROURACIL; GLUTATHIONE; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0035149476     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Characterization of resistance mechanisms to cis-diamminedichloroplatinum (II) in three sublines of the CC 531 colon adenocarcinoma cell line in vitro
2. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation
3. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
4. The role of glutathione in drug resistance
5. Overexpression of metallothionein confers resistance to anticancer drugs
6. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells
7. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer
8. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines
9. Potentiation of cisplatin against sensitive and resistant human ovarian cancer cell lines by amphotericin B
10. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II)
11. Hyperthermic enhancement of cytotoxicity and DNA-binding of cisplatin in sensitive and resistant human ovarian cancer cell lines
12. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD 437
13. Circumvention of cisplatin resistant ovarian cancer cells by antiestrogens
14. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST- 1 human squamous carcinoma cell line
15. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues
16. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity
17. Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
18. Excision repair of cis-diamminedichloroplatinum(II)-induced damage to DNA of Chinese hamster cells
19. Resistance to platinum compounds: Mechanisms and beyond
20. Ovarian carcinoma cells in culture: Assessment of drug sensitivity by clonogenic assay
21. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient
22. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate
23. Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin
24. Differential gene expression in human cancer cells resistant to cisplatin
25. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: Cross-resistance and protein changes
26. 5-Fluorouracil (FUra)
27. 5-Fluorouracil: A pharmacological paradigm in the use of cytotoxics
28. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells
29. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line
30. Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer
31. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
32. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
33. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinama cell lines
34. Inhibition by 5-fluorouracil of ERCC1 and γ-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line
35. Expression of the human DNA repair gene ERCC-1 relates to cisplatin drug resistance in human ovarian cancer cells
36. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line
37. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin
38. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion
39. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells